LIPOSOMAL ANTIVIRAL DRUG FOR ORAL USING

FIELD: medicine, virology. SUBSTANCE: invention proposes a drug for treatment of patients with viral infections. An agent is a lyophilizate or isotonic solution. Lyophilizate has the following components: recombinant interferon-alpha-2 (2.5-10) x 10 IU and also, mg: phosphatidylcholine 60-80; choles...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KOLOKOL'TSOV A.A, DLIN V.V, ZOLIN V.V, BARANOV JU.N, MARKARJAN A.S
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine, virology. SUBSTANCE: invention proposes a drug for treatment of patients with viral infections. An agent is a lyophilizate or isotonic solution. Lyophilizate has the following components: recombinant interferon-alpha-2 (2.5-10) x 10 IU and also, mg: phosphatidylcholine 60-80; cholesterol 6-10; alpha-tocopherol 6-10; ascorbic acid 1-2, and sucrose 40-90. An agent is stable in gastroenteric tract and absorbed in proximal part of small intestine. Agent is stable and does not hydrolyzed during absorption and has no show adverse effects. EFFECT: enhanced therapeutic effectiveness at oral intake. 1 tbl, 8 exa